Goldman Sachs Group Inc Keros Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 355,664 shares of KROS stock, worth $20.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
355,664
Previous 521,447 31.79%
Holding current value
$20.2 Million
Previous $23.8 Million 13.33%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$41.68 - $58.07 $6.91 Million - $9.63 Million
-165,783 Reduced 31.79%
355,664 $20.7 Million
Q2 2024

Aug 13, 2024
BUY
$44.58 - $66.89 $11.7 Million - $17.6 Million
263,079 Added 101.82%
521,447 $23.8 Million
Q1 2024

May 15, 2024
BUY
$41.26 - $70.48 $2.2 Million - $3.75 Million
53,269 Added 25.97%
258,368 $17.1 Million
Q4 2023

Feb 13, 2024
BUY
$27.12 - $41.05 $2.85 Million - $4.31 Million
105,040 Added 104.98%
205,099 $8.15 Million
Q3 2023

May 14, 2024
SELL
$31.57 - $43.02 $3.32 Million - $4.52 Million
-105,040 Reduced 51.21%
100,059 $3.19 Million
Q3 2023

Nov 14, 2023
BUY
$31.57 - $43.02 $825,618 - $1.13 Million
26,152 Added 35.39%
100,059 $3.19 Million
Q2 2023

May 14, 2024
BUY
$37.26 - $51.01 $433,967 - $594,113
11,647 Added 18.71%
73,907 $2.97 Million
Q2 2023

Aug 14, 2023
BUY
$37.26 - $51.01 $433,967 - $594,113
11,647 Added 18.71%
73,907 $2.97 Million
Q1 2023

May 14, 2024
SELL
$41.44 - $59.32 $3.46 Million - $4.96 Million
-83,562 Reduced 57.3%
62,260 $2.66 Million
Q1 2023

May 11, 2023
SELL
$41.44 - $59.32 $3.46 Million - $4.96 Million
-83,562 Reduced 57.3%
62,260 $2.66 Million
Q4 2022

May 14, 2024
SELL
$39.45 - $51.77 $1.2 Million - $1.58 Million
-30,542 Reduced 17.32%
145,822 $7 Million
Q4 2022

Feb 13, 2023
SELL
$39.45 - $51.77 $1.2 Million - $1.58 Million
-30,542 Reduced 17.32%
145,822 $7 Million
Q3 2022

May 14, 2024
BUY
$27.8 - $40.12 $792,661 - $1.14 Million
28,513 Added 19.28%
176,364 $6.64 Million
Q3 2022

Nov 10, 2022
BUY
$27.8 - $40.12 $792,661 - $1.14 Million
28,513 Added 19.28%
176,364 $6.63 Million
Q2 2022

May 14, 2024
SELL
$26.03 - $67.04 $1.49 Million - $3.84 Million
-57,248 Reduced 27.91%
147,851 $4.09 Million
Q2 2022

Aug 15, 2022
BUY
$26.03 - $67.04 $521,120 - $1.34 Million
20,020 Added 15.66%
147,851 $4.09 Million
Q1 2022

May 16, 2022
BUY
$42.12 - $59.36 $359,409 - $506,518
8,533 Added 7.15%
127,831 $6.95 Million
Q4 2021

Feb 14, 2022
BUY
$36.95 - $62.89 $2.49 Million - $4.24 Million
67,389 Added 129.82%
119,298 $6.98 Million
Q3 2021

Nov 10, 2021
BUY
$29.27 - $43.71 $1.52 Million - $2.27 Million
51,909 New
51,909 $2.05 Million

Others Institutions Holding KROS

# of Institutions
174
Shares Held
30.3M
Call Options Held
76.8K
Put Options Held
9K
View Full List

About Keros Therapeutics, Inc.

KROS Quotes by TradingView
  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.46B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email